Overall Fundamental outlook

* AJANTPHARM makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

Investors may react cautiously to news that AJANTPHARM's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 2.85400
forwardPE 26.47152
debtToEquity 1.25100
earningsGrowth 0.12100
revenueGrowth 0.11000
grossMargins 0.76963
operatingMargins 0.21557
trailingEps 73.45000
forwardEps 99.28000

AJANTPHARM's current ratio, being 2.854, means the company is well-positioned to meet its short-term debt obligations. This reflects AJANTPHARM's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
Ajanta Pharma Limited's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
Ajanta Pharma Limited's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with Ajanta Pharma Limited expected to increase its market presence and profitability.
AJANTPHARM's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
AJANTPHARM's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that AJANTPHARM is likely to outperform its previous year's financial performance.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

The price of Ajanta Pharma Limited has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


13 transactions to sell AJANTPHARM occurred, with market price at 2914.596153846154.No sell transactions were carried out during the period under review.Investors have shown more interest in buying than selling AJANTPHARM at current price levels, which may point to a positive market sentiment. This could indicate that investors are expecting favorable results from the stock in the near future.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts have shown a buy bias for Ajanta Pharma Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Ajanta Pharma Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.